# OnCo record nct04662255 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04662255/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04662255", "NCT04662255" ;
  schema:name "Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)"@en ;
  schema:alternateName "BRUIN MCL-321"@en ;
  schema:description "A phase 3 trial of Pirtobrutinib, Ibrutinib, Acalabrutinib and Zanubrutinib in mantle cell lymphoma, run by Loxo Oncology, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04662255/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04662255> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-04-08" ;
  onco:cancers <https://onco.cc/cancers/mantle-cell-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/zanubrutinib/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> .